JNJ-70218902 (JNJ-902), a TMEFF2 x CD3 bispecific antibody, in prostate cancer: Initial results from a phase I dose escalation study-MedSci.cn

JNJ-70218902 (JNJ-902), a TMEFF2 x CD3 bispecific antibody, in prostate cancer: Initial results from a phase I dose escalation study

Calvo, E; de Speville, BD; Galceran, JC; Peer, A; Sarid, DL; Eigl, BJ; Avadhani, A; Yao, D; Lin, V; Wu, S; Jaiprasart, P; Loffredo, J; Tamegnon, M; Xie, H; Hansen, AR

ANNALS OF ONCOLOGY, 2022; 33 (7): S1166

科室
- - 订阅+
  - 更多科室
工具
服务